UNSPSC 51351634: Conjugated estrogens/medroxyprogesterone acetate

Conjugated estrogens/medroxyprogesterone acetate (CEs/MPA) is a combination product of conjugated estrogens (Premarin), an estrogen, and medroxyprogesterone acetate (Provera), a progestogen, which is used in menopausal hormone therapy for the treatment of menopausal symptoms.

UNSPSC 51351634 Conjugated estrogens/medroxyprogesterone acetate is a Commodity code that shows minimal recent activity in state and local procurement. The code's nominal scope—hormonal pharmaceutical products—does not align with the recent opportunities tagged under it. Of the nineteen records in the most-recent-opportunities block, only two carry pharmaceutical or healthcare procurement signals: Seminole County's June 2026 IFB for naloxone and drug deactivation systems (a life-safety pharmaceutical distinct from hormone replacement therapy), and Tucson Fire Department's June 2026 RFP for BLS/ALS pharmaceuticals and vending machines (emergency medical supplies, not endocrine therapeutics). The remaining records are vendor outreach events (trade shows, open houses, vendor forums), networking platforms (NIGP reverse trade shows, meet-and-greets), a departmental relocation notice unrelated to procurement, and a county grant solicitation for opioid treatment capital projects. A single record—the MMCAP January 2026 RFP for generic multi-source pharmaceuticals and OTC products distributed through a cooperative purchasing vehicle—approaches the code's therapeutic scope but targets bulk hospital and public-facility dispensing rather than the patient-facing retail or clinic distribution channels typically associated with hormone replacement therapy products.

The near-absence of relevant solicitations under this code suggests either that conjugated estrogens/medroxyprogesterone acetate products are procured infrequently by state and local entities, are tagged to different UNSPSC codes in practice, or are sourced through standing cooperative agreements and master contracts rather than open competitive RFPs and RFQs. No geographic concentration, repeat-buyer pattern, or issuing-body type emerges from the available records. Vendors evaluating this code should verify current cooperative purchasing vehicles (such as MMCAP, state pharmaceutical consortia, or HMO master agreements) to identify actual procurement pathways, as traditional open solicitation activity does not support active business development under this code at present.